NCT04673591View on ClinicalTrials.gov

Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions

Allergy to House Dust MiteAllergic Asthma

Interventions

DRUG

Tregalizumab

a monoclonal antibody designed for the treatment of allergic asthma indication

OTHER

Placebo

Matched Placebo

Trial Locations (1)

Unknown

Medaimun GmbH, Frankfurt

All Listed Sponsors

lead

T-Balance Therapeutics GmbH

INDUSTRY

NCT04673591 - Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients | Biotech Hunter | Biotech Hunter